Article ; Online: ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells.
2021 Volume 37, Issue 4, Page(s) 109880
Abstract: Targeting mitochondrial metabolism has emerged as a treatment option for cancer patients. The ABL tyrosine kinases promote metastasis, and enhanced ABL signaling is associated with a poor prognosis in lung adenocarcinoma patients. Here we show that ABL ... ...
Abstract | Targeting mitochondrial metabolism has emerged as a treatment option for cancer patients. The ABL tyrosine kinases promote metastasis, and enhanced ABL signaling is associated with a poor prognosis in lung adenocarcinoma patients. Here we show that ABL kinase allosteric inhibitors impair mitochondrial integrity and decrease oxidative phosphorylation. To identify metabolic vulnerabilities that enhance this phenotype, we utilized a CRISPR/Cas9 loss-of-function screen and identified HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway and target of statin therapies, as a top-scoring sensitizer to ABL inhibition. Combination treatment with ABL allosteric inhibitors and statins decreases metastatic lung cancer cell survival in vitro in a synergistic manner. Notably, combination therapy in mouse models of lung cancer brain metastasis and therapy resistance impairs metastatic colonization with a concomitant increase in animal survival. Thus, metabolic combination therapy might be effective to decrease metastatic outgrowth, leading to increased survival for lung cancer patients with advanced disease. |
---|---|
MeSH term(s) | Allosteric Regulation/drug effects ; Allosteric Regulation/genetics ; Animals ; Apoptosis/drug effects ; Apoptosis/genetics ; Cell Line, Tumor ; Drug Synergism ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/enzymology ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Mice ; Mice, Nude ; Neoplasm Metastasis ; Oncogene Proteins v-abl/antagonists & inhibitors ; Oncogene Proteins v-abl/genetics ; Oncogene Proteins v-abl/metabolism ; Protein Kinase Inhibitors/pharmacology ; Signal Transduction/drug effects ; Signal Transduction/genetics ; Xenograft Model Antitumor Assays |
Chemical Substances | Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Oncogene Proteins v-abl ; Protein Kinase Inhibitors |
Language | English |
Publishing date | 2021-10-27 |
Publishing country | United States |
Document type | Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S. |
ZDB-ID | 2649101-1 |
ISSN | 2211-1247 ; 2211-1247 |
ISSN (online) | 2211-1247 |
ISSN | 2211-1247 |
DOI | 10.1016/j.celrep.2021.109880 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.